Drs. Jack West and Greg Riely field questions about which treatments should EGFR lung cancer patients consider when their cancers progress.

Dr. Jack West suggests that progression in T790M-negative EGFR lung cancer patients may not require a change in therapy. In this video he details what should go into the decision to modify treatment for those patients.

Acquired resistance in EGFR patients is often driven by the T790M mutation. T790M-positive tumors respond differently to treatments than T790M-negative tumors. Dr. Greg Riely details how each status can predict patients' responses to current treatments.

There are sub-types within the sub-type of EGFR mutation positive lung cancer. In this presentation, Dr. Jack West discusses the different activating mutations within EGFR positive tumors and how they impact treatment.

Janet Daily-Freeman moderates a question & answer session with Drs. Leora Horn and Taofeek Owonikoko on issues of acquired resistance to targeted therapies for ALK+ and ROS1 patients.

The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier.

Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owonikoko outlines these options for patients.

Dr. West moderates a question & answer session with Drs. Leora Horn and Greg Riely on issues of acquired resistance to targeted therapies for patients with advanced NSCLC that harbors a driver mutation.

Dr. Greg Riely from Memorial Sloan-Kettering Cancer Center reviews the limited data that help clarify the probability of benefit from new immunotherapy agents among patients with advanced NSCLC and an identified driver mutation.

Dr. Leora Horn of Vanderbilt University reviews the rapidly evolving issue and growing value of repeat biopsies, including plasma sampling as a "liquid biopsy" option, in the setting of acquired resistance to a driver mutation in advanced NSCLC.